Analysts: Discount Eteplirsen Bad for Sarepta and 3 More Research Notes to Think About

Sarepta (NASDAQ:SRPT): Piper Jaffray lowered its price target for Sarepta to $41 from $50, citing a higher discount rate on Eteplirsen following the company’s second-quarter results. The firm keeps a Neutral rating on the stock.


Iron Mountain (NYSE:IRM): Barclays downgraded Iron Mountain from Overweight to Equal Weight due to a lower probability of a REIT conversion and a more modest near-term outlook. The price target suffered as well, dropping to $32 from $36.


SunEdison (NYSE:SUNE): Lazard Capital views the Wednesday pullback in shares of SunEdison as an overreaction and a buying opportunity. The firm does not expect SunEdison’s profitability on its existing pipeline to slowdown and has kept a Buy rating on the stock.


Given Imaging (NASDAQ:GIVN): Cantor increased its target on Given Imaging from $25 to $22 after the company reported stronger-than-expected second-quarter results. The firm believes that the results are strong, and it thinks the company has a number of upcoming positive catalysts. It keeps a Buy rating on the shares.


Don’t Miss: Bad News Obamacare: Americans Lack Insurance Understanding.